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Abstract 
Herein we describe fluorescent derivatives of vemurafenib to probe therapeutic BRAF inhibition in 
live cells and in vivo. The compounds were evaluated and compared by determining target binding, 
inhibition of mutant BRAF melanoma cell lines and live cell imaging. We show that 
vemurafenib-BODIPY is a superior imaging drug to visualize the targets of vemurafenib in live cells 
and in vivo in non-resistant and resistant melanoma tumors. 
Key words: fluorescence microscopy, imaging agents, kinase inhibitor, BRAF 
Introduction 
The discovery of genetic alterations that are 
principally responsible for the formation of cancer has 
provided the basis for advancing targeted therapies 
for patients with metastatic disease [1, 2]. The BRAF 
gene was identified as a driver oncogene in 2002 and 
shown to be the most commonly mutated oncogene in 
melanoma (50% of all cases) [3]. Furthermore, BRAF 
gene mutations are present in 30-50% of thyroid 
cancer, 30% of low-grade ovarian cancers and 15% of 
colon cancers as well as in a number of other 
malignancies (totaling 7% of all human cancer 
diseases) [4], but additional BRAF-mutated forms are 
still being identified [5]. The BRAF protein is a 
member of the Raf family of serine threonine kinases, 
which are part of the Ras/RAF/MEK/ERK mitogen 
activated protein kinase (MAPK) signal transduction 
cascade that controls cell proliferation and survival 
(Fig. 1) [6]. The most common and best studied 
mutation of the BRAF gene is the glutamic acid 
substitution of valine at position 600 (V600E) within 
the kinase domain. This mutation results in a protein 
that remains in the active confirmation with an 
800-fold increased kinase activity compared with its 
wild-type counterpart, leading to uncontrolled 
proliferation and growth of cells expressing 
BRAFV600E [7]. 
Vemurafenib (Vem, PLX4032, Plexxikon/Roche) 
is a small molecule, non-covalent tyrosine kinase 
inhibitor primarily directed towards the BRAFV600E 
mutation. It acts in a competitive manner to limit ATP 
binding, thereby reducing activation of the MAPK 
pathway and cell proliferation. Vemurafenib is 
clinically approved for the treatment of metastatic and 
non-resectable melanoma that harbor the BRAFV600E 
mutation. As a monotherapy, it substantially 
increases efficacy with an overall response rate of 
48%, compared to 5% with chemotherapy using 
dacarbazine [8]. However, a durable response 
requires near-complete inhibition of the BRAF 
pathway, requiring the administration of relatively 
large doses of the drug (960 mg twice a day) and 
prolonged systemic drug exposure (area under the 
curve: AUC0-24 >300 μM h) [9]. Furthermore, roughly 
half of patients do not respond suggesting the 
predisposition to drug resistance, and those who 
initially respond eventually develop resistance after 
only a few months. 
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Figure 1. Development of fluorescently labeled vemurafenib imaging agents. (a) Folded structure of mutant BRAFV600E protein with vemurafenib inside 
the ATP binding site (PDB: 3OG7); (b) Synthesized fluorescent derivatives 1-6 of vemurafenib. 
 
 
The mechanisms driving the inadequate 
duration of response have yet to be fully appreciated, 
and several studies indicate that intrinsic and 
acquired resistance are the leading culprits [10-14]. 
However, other factors include: complex 
poly-pharmacodynamics [15], high cell-to-cell 
variability in both epigenetic and genetic properties of 
melanoma [16, 17], and influences of the tumor 
microenvironment to limit effective drug distribution 
[18].  
Pharmacokinetic imaging of fluorescent drug 
derivatives at the cellular and sub-cellular level can 
reveal novel insight into drug action in vivo, including 
target selectivity, kinetics, drug exposure, the 
presence of resistance mechanisms, and 
pharmacodynamic effects [19-22].  
Here we present the development and validation 
of fluorescent imaging agents based on the structure 
of vemurafenib, a non-covalent inhibitor that is 
known to display similar potency for several 
cytoplasmic targets, e.g. SRMS (18nM), ACK1 (19nM), 
BRAFV600E (31nM), c-RAF-1 (48nM) and even 
wild-type BRAF with only 3-fold less potency (100 
nM) compared to the mutant form [9].  
Given its polypharmacological nature, we focused on 
the visualization of all targets of vemurafenib. To the 
best of our knowledge, besides immunofluorescence 
using commercially available BRAF antibodies (e.g. 
abcam, LSBio) no imaging agent for BRAF or any 
BRAF inhibitor has been reported so far. 
Materials and Methods 
Chemical Synthesis and Compound 
Characterization 
A detailed description of the synthesis of all 
fluorescent vemurafenib derivatives and copies of 
NMR spectra can be found in the Supplementary 
Materials. 
Cell Lines 
The vemurafenib-resistant and non-resistant 
A375 and SK-MEL-28 cell lines were generously 
provided by Ji Zhenyu and Hensin Tsao 
(Massachusetts General Hospital, Boston, MA, USA). 
A375 and SK-MEL-28 cells (both resistant and 
non-resistant) were grown in Dublecos Minimum 
Essential Media (DMEM) or Minimum Essential 
Media (MEM) respectively. The media was 
supplemented with 10% fetal bovine serum, 100 I.U. 
penicillin, 100 μg/mL streptomycin, and 2 mM 
L-glutamine. The following quality controls have 
been performed in all cell culture experiments: 
mycoplasma testing (negative), monitoring of cell 
growth, cell size and morphology. We have not 
observed any effects on the morphology of all used 
melanoma cells after treatment with vemurafenib, 
vemurafenib-dye conjugates or both as described in 
this study. 
Cell Viability and BRAFV600E Binding Affinity 
For cell proliferation/viability assays, cells were 
plated at 5000 cells per well in 96-well plates (Corning 
assay well plates, Corning, NY, USA) and grown for 
24 hrs. Cells were then treated with increasing 
concentrations of vemurafenib derivatives (0 nM, 
0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 
1 µM, 10 µM, 50 µM) for 72 hrs. PrestoBlue® Cell 
Viability Reagent (ThermoFisher Scientific) was 
added as a 10X solution and plates were read out on a 
Tecan Safire 2 Platereader (Tecan Trading AG, 
Switzerland) after 10-30 min. The binding affinity of 
vemurafenib derivatives to BRAFV600E was assayed 
using the LanthaScreen® Eu Kinase Binding Assay 
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(ThermoFisher Scientific) following the 
manufacturer’s protocol. All reagents and BRAF 
recombinant human protein (sold as BRAF[V599E], 
which is equivalent to BRAFV600E) were purchased 
from ThermoFisher Scientific/Life technologies. Low 
volume 384-well plates (Corning, NY, USA) were 
used and read out using a Perkin Elmer EnVision 
Multilabel Reader (Waltham, MA, USA). 
BFP and Apple expressing A375 cell lines 
For in vivo experiments H2B-BFP A375 and 
H2B-Apple A375R cells lines were constructed 
through transduction with a pTag-H2B-BFP or 
pTag-H2B-Apple construct, respectively, using 
X-tremeGENE HP transfection reagent (Roches). 
Single clones were selected using fluorescent 
activated cell sorting, choosing the top 10% brightest 
cells. Fluorescent cells were maintained in the 
previously described DMEM media with the addition 
of 1.5 μg/mL of puromycin.  
Live cell fluorescence microscopic imaging  
SK-MEL-28 and A375 cells were plated at 30000 
cells per well in 96-well plates (µ-Plate 96 Well 
ibiTreat: #1.5 polymer coverslip, tissue culture 
treated, sterilized; ibidi, Madison, WI, USA) and 
grown for 24 hrs. On the day of imaging, cells were 
incubated with a final concentration of 1 μM (0.1% 
dimethyl sulfoxide (DMSO) in growth media) of 
vemurafenib derivatives for 60 min at 37°C. Cells 
were washed three times with media (15 min each) 
and live cells were imaged in a humidified 
environmental chamber of a DeltaVision microscope 
(Applied Precision, Issaquah, WA). High-resolution 
imaging in melanoma cells was carried out as 
described above using a customized Olympus FV1000 
system based on a BX61-WI confocal microscope 
(Olympus America). 
Competition imaging experiment  
A375, A375R, SK-MEL-28, and SK-MEL-28R cells 
were plated at 30000 cells per well in 96-well plates 
(µ-Plate 96 Well ibiTreat: #1.5 polymer coverslip, 
tissue culture treated, sterilized; ibidi, Madison, WI, 
USA) and were grown for 24 hrs. On the day of 
imaging, cells were incubated with 0, 1, 5, 10, 50, and 
100 μM concentrations of vemurafenib (0.1% DMSO 
in growth media) for 30 min at 37°C. Without 
washing, cells were co-incubated with fluorescent 
vemurafenib derivatives (1 μM final concentration in 
growth media) and vemurafenib for 120 min at 37°C. 
Cells were washed three times with media (15 min 
each) and live cells were imaged in a humidified 
environmental chamber of a DeltaVision microscope 
(Applied Precision, Issaquah, WA).  
Intravital imaging 
All animal experiments were carried out in 
accordance with guidelines from the Institutional 
Subcommittee on Research Animal Care. Nude mice 
(Cox7, Massachusetts General Hospital) were 
surgically implanted with a dorsal skin window 
chamber. Approximately 5×106 A375 cells co-mixed 
with 1×106 A375R cells (5:1 ratio), suspended in 
phosphate buffered saline (PBS), were implanted 
under the fascia and allowed to grow for ∼10 to 12 
days. As A375R cells showed faster proliferation rates 
we empirically found that using a 5:1 ratio 
(A375:A375R) at time of implantation yields similar 
cell counts at time of imaging several days later. This 
facilitates a balanced analysis in both cell types. As 
soon as the tumors became vascularized and had 
reached 1–2 mm in size, mice were anesthetized with 
2% isoflurane in 2 L/minute oxygen on a heated 
microscope stage. They were then injected via a lateral 
tail vein catheter with 50 µL of Angiospark-680 
(Perkin Elmer, Waltham, MA) or 2 MDa 
amino-dextran labeled with FITC 
N-hydroxysuccinimide (NHS) ester (Invitrogen, 
Grand Island, NY). Vascularized regions of interest in 
the tumor were identified by the vessel probe and by 
the H2B-BFP and H2B-Apple tumor signals; regions 
with minimal out-of-plane vessels and a substantial 
mixture of vemurafenib-resistant and non-resistant 
A375 cells were chosen for imaging. Imaging was 
initiated prior to injection of fluorescently labeled 
drug, which was formulated by dissolving 4 µL of a 50 
mM solution in DMSO followed by adding an 
additional 11 µL of DMSO and 15 µL of solutol. 120 µL 
of PBS was then slowly added and vortexed for 1 
minute to obtain a final injection volume of 150 µL. 
Hence, 200 nmol of vemurafenib-dye derivative have 
been injected resulting in an approximate dose of 
10 µmol/kg. Measurements were repeated in five 
tumor bearing mice.  
Images were collected as a function of depth 
(z-stack, 4 µm step size) using a customized Olympus 
FV1000 system based on a BX61-WI confocal 
microscope (Olympus America). A XLUMPLFLN 20× 
water immersion objective (NA 1.0, Olympus 
America) was used for data collection. BODIPY 
(boron dipyrromethene), H2B-Apple, and vascular 
probes were scanned and excited sequentially using a 
405 nm, a 473-nm, a 559-nm and/or a 633 nm diode 
laser, respectively, in combination with a DM405 
488/559/635-nm dichroic beam splitter. Emitted light 
was then separated and collected using appropriate 
combinations of beam splitters (SDM473, SDM560, 
and/or SDM 640) and emission filters BA430–455, 
BA490–540, BA575–620, BA575–675, and/or 
BA655–755 (all Olympus America). A separate cohort 
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of tumors was used to determine appropriate voltage 
and laser power settings to minimize saturation and 
to ensure that no photobleaching or phototoxicity 
occurred. The z-stacks were acquired at 0 h, 1 h, 3 h, 7 
h, and 24 h post-injection of the fluorescent derivative. 
Analysis of Single-Cell Pharmacokinetics 
Quantification of the single-cell intensity of the 
fluorescent derivative was performed using 
CellProfiler [23]. The zStacks were imported into 
CellProfiler and the nuclei were segmented using an 
automatic thresholding algorithm to identify 
non-resistant (H2B-BFP) and resistant (H2B-Apple) 
A375 cells. A region growing algorithm was used to 
extend the previously identified nuclear region, 
followed by taking the difference between the 
extended and nuclei regions to isolate the cytoplasm. 
CellProfiler automatically ensured non-overlapping 
cytoplasmic regions between cells. The analysis was 
performed on each slice in the zStack and the mean 
cytoplasm intensity was record for cell. The data was 
imported into MATLAB, plotted for each mouse and 
time point as a function of depth. The data was then 
filtered to exclude cells with saturation signal and 
slices at a depth whereby substantial attenuation of 
light limited the ability for accurate quantification. 
The final single-cell data was conglomerated for each 
mouse and plotted as a function of time. The 
single-cell intensities were normalized to the median 
pre-injection intensity.  
Results and Discussion 
We sought to identify a derivative with optimal 
pharmacokinetics and imaging characteristics. 
Structural analysis of binding between vemurafenib 
and the folded BRAFV600E protein suggests that the 
p-chlorophenyl substituent on vemurafenib could be 
labeled with minimal perturbation to drug binding 
(Fig. 1a). This assumption is supported by the similar 
binding affinities and properties of vemurafenib and 
the related BRAFV600E inhibitor PLX4720 [5, 15], which 
does not contain the p-chlorophenyl group (Fig. S1).  
Aiming for an imaging agent it would have been 
possible to select PLX4720 as core structure, but 
considering the folded structure of mutant BRAF with 
the drug inside the binding site (Fig. 1a) and the 
required distance between the pocket and a sterically 
demanding fluorescent dye we preferred to use the 
core structure of vemurafenib. 
Starting from a vemurafenib precursor a 
modifiable derivative was synthesized by replacing 
p-chlorophenyl with p-aminophenyl generating a free 
NH2 group for further modification. This intermediate 
was conjugated to different fluorophores with or 
without a short linker in-between (Fig. S2). We 
focused on three known fluorescent moieties with 
different physical properties to obtain a library of six 
vemurafenib-fluorescent dye conjugates (Fig. 1b). In 
general, the amounts of fluorophore used in 
molecular imaging probes are typically much lower 
than the toxic doses described in the literature [24].  
BODIPY (boron dipyrromethene) has frequently 
been used as fluorescent dye for the preparation of 
imaging drugs [21, 25-31]. In this study a slightly 
modified BODIPY (substituted BODIPY® 505/515) 
was used for the preparation of conjugates 1 and 2. 
Recently, Courtis et al. reported a method to modify 
the core structure of BODIPY by replacing a fluorine 
with ethylene glycol leading to the development of 
MayaFluor dyes that exhibit increased hydrophilicity 
and improved properties for imaging applications 
[32]. The BODIPY derivative previously used for the 
preparation of 1 and 2 was modified to obtain a 
carboxyl-modified MayaFluor, which was then used 
for the synthesis of 3 and 4. Furthermore, silicon 
rhodamines (SiR) have emerged as highly promising 
fluorescent dyes for the synthesis of imaging probes 
[20, 33-38] and it was shown that carboxylated silicon 
rhodamine (SiRC, SiR-COOH) is advantageous over 
other SiR derivatives [39]. Hence, SiRC was used in 
this study for the preparation of 5 and 6. Selected 
physical properties of all synthesized vemurafenib 
derivatives (1-6) are summarized in Table S1, for 
synthetic details see Supporting Information and Fig. 
S2.  
 We next set out to determine whether 1-6 (i) 
bind to BRAFV600E with similar pharmacological 
activity (EC50), (ii) are cell membrane permeable and 
localize to the cytoplasm, the main site of BRAFV600E 
expression, and (iii) can be competitively blocked by 
the parent compound in vitro. Due to the 
poly-pharmacological nature of vemurafenib, the 
competitive imaging assay provided a test of the 
drug-dye conjugates’ ability to mimic the target 
specificity of vemurafenib. Two melanoma cell lines 
were chosen for in vitro characterization: A375 and 
SK-MEL-28. Of the six drug-dye conjugates, 1 
(Vemurafenib-BODIPY), 3 (Vemurafenib-MayaFluor), 
and 6 (Vemurafenib-Linker-SiRC) have EC50 values for 
inhibition of proliferation and binding affinities 
comparable to the parent drug (Fig. 2a). Live cell 
imaging showed that 1 efficiently penetrates into the 
cytoplasm of melanoma cells and has prolonged 
retention (Fig. 2b). In comparison, the efficiency of 
cytoplasmic penetration and retention of 3 is poor. 6 
showed efficient penetration, but rapid efflux 
suggested limited target engagement and/or rapid 
dissociation kinetics. We hypothesize that attaching a 
hydrophilic moiety (e.g. MayaFluor, SiRC or short 
polyethyleneglycol (PEG)- linkers) leads to faster 
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dissociation from the target, whereas lipophilic 
BODIPY might serve as a ‘hydrophobic lid’ 
preventing rapid exchange of bound 1 by water. 
Moreover, these findings and our hypothesis could 
also explain the improved properties of vemurafenib 
compared to PLX4720 despite similar target affinity 
[5, 15] due to increased hydrophobicity caused by the 
additional p-chlorophenyl substituent (Fig. S1). 
Live cell imaging using laser scanning 
microscopy showed that 1 distributes predominantly 
within the cytosol of both melanoma cell lines (Fig. 
2c). Previous studies have reported sub-cellular 
localization of BRAFV600E primarily within the cytosol 
[40], in agreement with our observations. Other 
reports have suggested BRAFV600E may also localize to 
the mitochondria and Golgi apparatus, but this was 
not directly observed in our study [41, 42]. 
Competitive imaging revealed that apriori 
exposure of live cells to vemurafenib efficiently 
blocked the binding of 1 in a dose dependent manner 
(reasonable for a non-covalent inhibitor) 
demonstrating a similar target specificity compared to 
vemurafenib (Fig. 3 and Fig. S3). The sub-cellular 
localization, target specificity, and slow dissociation 
kinetics further demonstrate that 1 is an exemplary 
imaging agent to visualize the targets of vemurafenib. 
 
 
 
Figure 2. In vitro assays identify vemurafenib-BODIPY (1) as a superior imaging agent. (a) Inhibition of proliferation and binding affinity (EC50, nM; 
standard error of logEC50 in parentheses) of 1, 3 and 6 were closely associated with the parent compound. All compounds showed EC50 values >5000 nM for 
inhibition of the proliferation of resistant cells. (b) In vitro imaging of 1 demonstrates prolonged cytoplasmic retention with minimal background fluorescence, in 
contrast to 3 and 6, in SK-MEL-28 cells. [blue: HOECHST 33342, green: BODIPY, red: SiRC] (c) High-resolution microscopy of 1in an A375 cell and SK-MEL-28 cells 
(inset). 
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Figure 3. Competitive imaging demonstrates the target specificity of 1. Imaging of 1 (Vemurafenib-BODIPY, 1 μM) in SK-MEL-28 cells in competition with 
increasing concentrations (0- to 100-fold excess) of parent drug vemurafenib (Vem); data presented as mean ± SD normalized to the 0-fold measurements [blue: 
HOECHST 33342, green: BODIPY].  
 
We next explored the single-cell 
pharmacokinetics (PK) in vivo of the leading 
compound 1, vemurafenib-BODIPY (Fig. 4a). In vivo 
experiments were performed in a dorsal skin fold 
window chamber model inoculated with a mixed 
population of vemurafenib-resistant A375 H2B-Apple 
cells (A375R; EC50 > 5000 nM for inhibition of 
proliferation) and non-resistant A375 H2B-BFP (A375; 
EC50 = 160 nM for inhibition of proliferation). 
Subcellular color-coded in vivo imaging was 
performed based on previously reported methods 
[43-45]. Single-cell analysis of in vivo PK imaging was 
performed using CellProfiler (see Materials and 
Methods, and Fig. S4). 1 was administered through 
the tail vein at a dose of 8 mg/kg (equivalent to 5 
mg/kg of the parent drug vemurafenib). The agent 
rapidly diffused across the tumor and penetrated into 
A375/A375R cells over the course of 1 h. Clearance 
from the vasculature and interstitial compartment 
was observed at 3-7 h post-injection, while the agent 
remained inside the A375/A375R cells. Minimal 
residual agent was detected in the tumor at 24 h. In 
comparison, in vivo PK imaging of 3 and 6 showed 
non-specific binding to collagen fibers at 1 h, and 
negligible tumor cell uptake after 5 h (Fig. S5). 
Quantification of the single-cell kinetics of 1 
made in five separate tumors revealed remarkable 
spatio-temporal heterogeneity in tumor cell uptake 
and retention (Fig. 4b), which has also been compared 
to the heterogeneous uptake of vemurafenib-BODIPY 
in vitro as observed by live cell fluorescence 
microscopy showing a significantly wider range in 
vivo (Fig. S6). Peak intensity was observed at 1 h post 
injection, and also had the largest intercellular 
heterogeneity in uptake. The single-cell heterogeneity 
was driven primarily by the proximity of cells to 
blood vessels, with high-local concentrations of the 
agent found in cells closest to vasculature. At 3 h, the 
single-cell heterogeneity more closely reflects 
variations in the intrinsic cell properties, such as 
target expression. The heterogeneous delivery of 1 
reflects substantial variability in target engagement 
and may help explain the initial explosive response 
but limited duration following vemurafenib treatment 
[9, 46, 47] due to the intercellular heterogeneity of the 
drug concentration in the tumor.  
Several mechanisms of acquired resistance have 
been explored for vemurafenib, including: BRAFV600E 
over-expression (amplification) [12, 48], bypass of 
BRAFV600E inhibition through activation of 
complimentary pathways [49], and target 
modification for example through the emergence of 
spliced BRAFV600E that retains the ability to dimerize 
and activate the MAPK signaling pathway [11]. It is 
anticipated that the latter two mechanisms do not 
significantly alter the single-cell PK of vemurafenib. 
We observed only negligible differences in single-cell 
PK between vemurafenib-resistant and non-resistant 
A375 melanoma cells. These results are congruent 
with the hypothesis that A375R cells expressing a 
spliced variant of BRAFV600E will have similar binding 
kinetics for vemurafenib [50].  
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Figure 4. In vivo imaging reveals the pharmacokinetics of 1 in melanoma. (a) 1 rapidly transports across blood vessels, through the interstitium and 
accumulates in all cells. (b) PK imaging and quantification of single-cell kinetics reveals specific retention in vemurafenib-resistant (A375R) and non-resistant (A375) 
melanoma cells. Each point represents the cytoplasmic intensity of vemurafenib-BOPIDY (1) in tumor cells (n=5 tumors). Data is normalized to the median of the 0 h 
measurements. Bars represent the median and interquartile range of the aggregated single-cell measurements. (c) Within 1 h the agent localizes to the cytoplasm of 
resistant and non-resistant A375 cells, perivascular cells (arrows), and other host cells (neutrophil-like cells; arrows). After 7 h 1 is retained in melanoma and 
neutrophil-like cells, but cleared from perivascular cells. 
 
Consistent with in vitro data, 1 was uniformly 
distributed in the cytoplasm of A375 and A375R 
tumor cells in vivo (Fig. 4c). We also observed the 
cytoplasmic uptake of the agent in non-tumor cells 
including perivascular, pericyte-like, cells in tumor 
and healthy tissue, and in host, neutrophil-like, cells. 
Vemurafenib-BODIPY (1) was not retained in 
perivascular cells, but was persistent in 
neutrophil-like cells at 7 h post-injection, which we 
hypothesize can be explained by the 
polypharmacological nature of vemurafenib. Binding 
to various targets with different affinities might be the 
reason for different PK properties in different cell 
types. These results may help further elucidate 
potential off-target effects of vemurafenib that may 
have enhancing or antagonistic ramifications towards 
tumor response, as well as contribute to toxicity. 
Conclusion 
In summary, we have synthesized and 
characterized several fluorescently labeled derivatives 
of the approved BRAF inhibitor vemurafenib. All 
compounds were evaluated focusing on binding 
properties, inhibition of proliferation of resistant and 
non-resistant melanoma cells, and by fluorescence 
microscopy. We finally identified vemurafenib- 
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BODIPY as a superior imaging agent to visualize the 
intracellular targets of vemurafenib and showed its 
application in live cell and in vivo imaging. We 
observed heterogeneous delivery to xenografted 
melanoma tumors, similar accumulation in resistant 
and non-resistant A375 melanoma cells, and retention 
in host cells.  
We aim to use our probe to study the 
polypharmacological properties of vemurafenib in 
other types of melanoma focusing on various 
mechanisms of resistance, and to investigate target 
distribution and drug uptake of tumors during 
treatment. In combination with a recently reported 
mouse model vemurafenib-BODIPY can further be 
used to study patient derived orthotopic xenografts 
with emphasis on intrinsic and acquired resistance 
[51]. In case of resistance through amplification of 
BRAFV600E vemurafenib-BODIPY might even be 
applied to distinguish sensitive and resistant cancer 
cells. Overall, we are convinced that our new imaging 
agent and the reported findings will lead to several 
applications and help achieving a better 
understanding of the underlying mechanisms of 
BRAF inhibition and vemurafenib treatment. 
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